NEW DELHI: Biotechnology firm Biocon on Thursday said its consolidated profit after tax rose over six-fold to Rs 660 crore in the first quarter ended June 2024, on account of a one-time gain from the collaboration between Biocon Biologics and Eris Lifesciences.
